Solabia Acquires Mibelle Biochemistry, Seqens' Botanical Actives and IVD Activity, and Xebios Group
March 5, 2026
Solabia, a Paris-headquartered biotech platform focused on natural active ingredients and diagnostics solutions, has agreed to acquire three complementary businesses as part of its international expansion strategy. The acquisitions include Switzerland-based Mibelle Biochemistry, France-based Seqens' Botanical Actives and In-Vitro Diagnostics activity, and Germany/Netherlands-based Xebios Group.
- Buyers
- Solabia, Astorg, TA Associates
- Targets
- Mibelle Biochemistry, Seqens' Botanical Actives and In-Vitro Diagnostics Activity, Xebios Group
- Platforms
- Solabia
- Industry
- Biotechnology
- Location
- France
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
Viome Acquires Sōlaria Biō to Expand Into Clinically Validated Synbiotics and Medical Foods
October 9, 2026
Healthcare Services
Viome acquired Sōlaria Biō, a clinically validated synbiotics and medical foods company, to expand its personalized health platform into condition-specific interventions. The deal brings Sōlaria’s microbial discovery platform, biobank, machine-learning capabilities, and products—most notably its standalone synbiotic medical food Bōndia—into Viome’s portfolio.
-
ICL Acquires Majority of Lavie Bio's Activities and Assets from Evogene
July 8, 2025
Biotechnology
ICL Group Ltd. has completed the acquisition of the majority of activities and assets of Lavie Bio Ltd., Evogene's ag-biologicals subsidiary, including Lavie Bio's BDD technology platform, microbial bank, pipeline and current commercial products. Evogene also transferred its MicroBoost AI tech-engine for agriculture to ICL as part of the divestiture; Lavie Bio core personnel will move to ICL while certain strategic partnerships remain with Lavie Bio.
-
Astorg to Acquire Majority Stake in Solabia Group
May 7, 2025
Biotechnology
Astorg has signed a definitive agreement to acquire a majority stake in Solabia Group from TA Associates, with TA reinvesting alongside Astorg. Solabia, a Paris-headquartered biotech ingredients manufacturer with 11 production sites, 8 R&D labs and over 900 employees, will partner with Astorg to accelerate international expansion (particularly in the US and Asia), advance product innovation and pursue targeted M&A.
-
Azelis Acquires Solchem Nature S.L. to Strengthen Nutraceutical Offering in Spain
April 7, 2025
Food & Beverage
Azelis has acquired 100% of Solchem Nature S.L., a Barcelona-based distributor of raw materials and premium ingredients for the nutraceutical and dietary supplements market. The deal expands Azelis's presence in Spain and adds Solchem's ~14-person team and network of over 250 customers to Azelis's EMEA nutraceutical platform.
-
Optibrium Acquires BioPharmics LLC
August 31, 2023
Software
Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.
-
Abenex Acquires Cisbio Bioassays from Argos Soditic
June 16, 2016
Biotechnology
French private equity firm Abenex has acquired Cisbio Bioassays from seller Argos Soditic. Abenex will partner with the biotech to support its organic and external growth strategy across pharmaceutical research and in vitro diagnostics; Cisbio has ~210 employees and generates over 85% of revenue outside France.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.